Cervical cancer risk in association with TNF-alpha gene polymorphisms in Bangladeshi women.

Q3 Biochemistry, Genetics and Molecular Biology

Tumor Biology Pub Date : 2024-01-01 DOI:10.3233/TUB-240002

Zasia Hossain Tishe, Sanjana Shawkat, Meherun Nessa Popy, Sadia Biswas Mumu, Annur Ferdous, Munira Jahan Raisa, Mehedi Hasan, Taposhi Nahid Sultana, Nusrat Islam Chaity, Mohd Nazmul Hasan Apu, Md Shaki Mostaid

{"title":"Cervical cancer risk in association with TNF-alpha gene polymorphisms in Bangladeshi women.","authors":"Zasia Hossain Tishe, Sanjana Shawkat, Meherun Nessa Popy, Sadia Biswas Mumu, Annur Ferdous, Munira Jahan Raisa, Mehedi Hasan, Taposhi Nahid Sultana, Nusrat Islam Chaity, Mohd Nazmul Hasan Apu, Md Shaki Mostaid","doi":"10.3233/TUB-240002","DOIUrl":null,"url":null,"abstract":"Background: Tumor necrosis factor-alpha (TNF-α) is among the vital pro-inflammatory cytokines that potentially exerts a significant influence on the immune response, hence potentially regulating the advancement of cervical lesions.Objective: Our study objective was to examine the relationship between two single nucleotide polymorphisms (SNPs) (rs1799724 and rs1800629) of TNF-α and the risk of cervical cancer in women from Bangladesh.Methods: We recruited 133 patients with cervical cancer and 126 healthy individuals for this study. Genotyping was performed using real-time PCR SNP genotyping assay. Multivariate logistic regression analysis was used to determine the odds ratio (OR) along with 95% confidence intervals (CI) and p-values.Results: For rs1799724 (C > T) polymorphism, TT mutant homozygous genotype carried 3.26 times increased risk of developing cervical cancer (OR = 3.26, 95% CI = 1.15-9.28, p = 0.027). Polymorphism of rs1800629 (G > A) was also related to an elevated risk of cervical cancer. Individuals with the AG heterozygous genotype (OR = 2.85, 95% CI = 1.20-6.74, p = 0.017) and AA mutant homozygous genotype (OR = 4.55, 95% CI = 1.24-16.60, p = 0.022) also had a higher likelihood of having cervical cancer. Moreover, we found that injectable contraceptives increase the risk of cervical cancer. Individuals who smoked and/or had first-degree relatives with cancer were more likely to carry the risk allele, which increases the likelihood of developing cervical cancer.Conclusion: TNF-α polymorphisms in rs1799724 and rs1800629 increase the susceptibility of developing cervical cancer in women from Bangladesh.","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":"46 1","pages":"13-24"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumor Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/TUB-240002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Tumor necrosis factor-alpha (TNF-α) is among the vital pro-inflammatory cytokines that potentially exerts a significant influence on the immune response, hence potentially regulating the advancement of cervical lesions.

Objective: Our study objective was to examine the relationship between two single nucleotide polymorphisms (SNPs) (rs1799724 and rs1800629) of TNF-α and the risk of cervical cancer in women from Bangladesh.

Methods: We recruited 133 patients with cervical cancer and 126 healthy individuals for this study. Genotyping was performed using real-time PCR SNP genotyping assay. Multivariate logistic regression analysis was used to determine the odds ratio (OR) along with 95% confidence intervals (CI) and p-values.

Results: For rs1799724 (C > T) polymorphism, TT mutant homozygous genotype carried 3.26 times increased risk of developing cervical cancer (OR = 3.26, 95% CI = 1.15-9.28, p = 0.027). Polymorphism of rs1800629 (G > A) was also related to an elevated risk of cervical cancer. Individuals with the AG heterozygous genotype (OR = 2.85, 95% CI = 1.20-6.74, p = 0.017) and AA mutant homozygous genotype (OR = 4.55, 95% CI = 1.24-16.60, p = 0.022) also had a higher likelihood of having cervical cancer. Moreover, we found that injectable contraceptives increase the risk of cervical cancer. Individuals who smoked and/or had first-degree relatives with cancer were more likely to carry the risk allele, which increases the likelihood of developing cervical cancer.

Conclusion: TNF-α polymorphisms in rs1799724 and rs1800629 increase the susceptibility of developing cervical cancer in women from Bangladesh.

查看原文本刊更多论文

孟加拉妇女患宫颈癌的风险与 TNF-α 基因多态性的关系。

背景：肿瘤坏死因子-α（TNF-α）是重要的促炎细胞因子之一，可能对免疫反应产生重要影响，从而可能调节宫颈病变的进展：我们的研究目的是探讨 TNF-α 的两个单核苷酸多态性（SNPs）（rs1799724 和 rs1800629）与孟加拉国妇女罹患宫颈癌风险之间的关系：本研究招募了 133 名宫颈癌患者和 126 名健康人。采用实时 PCR SNP 基因分型检测法进行基因分型。采用多变量逻辑回归分析来确定几率比（OR）、95% 置信区间（CI）和 p 值：rs1799724（C > T）多态性中，TT 突变同源基因型患宫颈癌的风险增加 3.26 倍（OR = 3.26，95% CI = 1.15-9.28，p = 0.027）。rs1800629的多态性（G > A）也与宫颈癌风险升高有关。AG杂合基因型（OR = 2.85，95% CI = 1.20-6.74，p = 0.017）和AA突变同源基因型（OR = 4.55，95% CI = 1.24-16.60，p = 0.022）的个体患宫颈癌的可能性也更高。此外，我们还发现注射避孕药会增加患宫颈癌的风险。吸烟和/或一级亲属中有人罹患癌症的人更有可能携带风险等位基因，这增加了罹患宫颈癌的可能性：结论：rs1799724 和 rs1800629 的 TNF-α 多态性会增加孟加拉国妇女患宫颈癌的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tumor Biology 医学-肿瘤学

CiteScore

5.40

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： Tumor Biology is a peer reviewed, international journal providing an open access forum for experimental and clinical cancer research. Tumor Biology covers all aspects of tumor markers, molecular biomarkers, tumor targeting, and mechanisms of tumor development and progression. Specific topics of interest include, but are not limited to: Pathway analyses, Non-coding RNAs, Circulating tumor cells, Liquid biopsies, Exosomes, Epigenetics, Cancer stem cells, Tumor immunology and immunotherapy, Tumor microenvironment, Targeted therapies, Therapy resistance Cancer genetics, Cancer risk screening. Studies in other areas of basic, clinical and translational cancer research are also considered in order to promote connections and discoveries across different disciplines. The journal publishes original articles, reviews, commentaries and guidelines on tumor marker use. All submissions are subject to rigorous peer review and are selected on the basis of whether the research is sound and deserves publication. Tumor Biology is the Official Journal of the International Society of Oncology and BioMarkers (ISOBM).